Second-generation antipsychotic medications in the treatment of mood disorders: Focus on aripiprazole

Drugs of Today

Volumn 41, Issue 1, 2005, Pages 5-11

  Buckley, Peter F ^a  

^a MEDICAL COLLEGE OF GEORGIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICONVULSIVE AGENT; ANTIDEPRESSANT AGENT; ARIPIPRAZOLE; CARBAMAZEPINE; CHOLESTEROL; CLOZAPINE; DOPAMINE 2 RECEPTOR; DOPAMINE 2 RECEPTOR STIMULATING AGENT; FLUOXETINE PLUS OLANZAPINE; GLUCOSE; HALOPERIDOL; HISTAMINE RECEPTOR; KETOCONAZOLE; LIPID; LITHIUM; LIVER ENZYME; MOOD STABILIZER; MUSCARINIC RECEPTOR; NEUROLEPTIC AGENT; OLANZAPINE; PERPHENAZINE; PLACEBO; PROLACTIN; QUETIAPINE; QUINIDINE; RISPERIDONE; SEROTONIN 1A AGONIST; UNINDEXED DRUG; VALPROIC ACID; ZIPRASIDONE;

AGRANULOCYTOSIS; BIPOLAR DISORDER; CLINICAL FEATURE; CLINICAL TRIAL; DEPRESSION; DRUG ABSORPTION; DRUG DOSE REGIMEN; DRUG EFFECT; DRUG EFFICACY; DRUG INDICATION; DRUG MECHANISM; DRUG METABOLISM; DRUG RECEPTOR BINDING; DRUG SAFETY; DRUG TOLERABILITY; DRUG UTILIZATION; EXTRAPYRAMIDAL SYMPTOM; HUMAN; LONG TERM CARE; MAINTENANCE THERAPY; MANIA; MOOD DISORDER; MOTOR DYSFUNCTION; OUTCOMES RESEARCH; PATIENT COMPLIANCE; QT PROLONGATION; REVIEW; SCHIZOPHRENIA; SEDATION; SEIZURE; SIDE EFFECT; TARDIVE DYSKINESIA; TREMOR; WEIGHT GAIN;

ANTIPSYCHOTIC AGENTS; HUMANS; MOOD DISORDERS; PIPERAZINES; QUINOLONES; SCHIZOPHRENIA;

EID: 15344338978     PISSN: 16993993     EISSN: 16994019     Source Type: Journal    
DOI: 10.1358/dot.2005.41.1.875774     Document Type: Review

References (50)

1. Hirschfield, R.M.A. The efficacy of atypical antipsychotics in bipolar disorders. J Clin Psychiatry 2003, 64 (Suppl. 8): 15-21.
2. Buckley, P.F. Broad therapeutic uses of atypical antipsychotic medications. Biol Psychiatry 2001, 50: 912-24.
3. Adller, C.M., Strakowski, S.M. The boundaries of schizophrenia. Psych Clin N America 2003, 26: 1-23.
4. American Psychiatric Association. Practice guideline for the treatment of patients with bipolar disorder (revision). Am J Psychiatry 2002, 159 (4 Suppl.): 1-50.
5. Scott, J., Pope, M. Nonadherence with mood stabilizers: Prevalence and predictors. J Clin Psychiatry 2002, 63: 384-90.
6. Bauer, M.S., Mitchner, L. What is a "mood stabilizer"? An evidence-based response. Am J Psychiatry 2004, 161: 3-18.
7. Keck, P.E., McElroy, S.L., Strakowski, S.M., Soutullo, C.A. Antipsychotics in the treatment of mood disorders and risk of tardive dyskinesia. J Clin Psychiatry 2000, 61 (Suppl. 4): 33-8.
8. Tonen, M., Sanger, T.M., McElroy, S.L. et al. Olanzapine versus placebo in the treatment of acute mania. Am J Psychiatry 1999, 156: 702-9.
9. Tonen, M., Jacobs, T.G., Grundy, S.L. et al. Efficacy of olanzapine in acute bipolar mania: A double-blind, placebo-controlled study. The Olanzapine HGGW Study Group. Arch Gen Psychiatry 2000, 57: 841-9.
10. Tohen, M., Baker, R.W., Altshuler, L.L. et al. Olanzapine versus divalproex in the treatment of acute mania. Am J Psychiatry 2002, 159: 1011-7.
11. Tohen, M., Chengappa, K.R., Suppes, T. et al. Efficacy of olanzapine in combination with valproate or lithium in the treatment of mania in patients partially nonresponsive to valproate or lithium monotherapy. Arch Gen Psychiatry 2002, 59: 62-9.
12. Zajecka, J.M., Weisler, R., Sachs, G. et al. A comparison of the efficacy, safety, and tolerability of divalproex sodium and olanzapine in the treatment of bipolar disorder. J Clin Psychiatry 2002, 63: 1148-55.
13. Tohen, M., Goldberg, J.F., Gonzalez-Pinto Arrillaga, A.M. et al. A 12-week, double-blind comparison of olanzapine vs haloperidol in the treatment of acute mania. Arch Gen Psychiatry 2003, 60: 1218-26.
14. Keck, P.E. Jr., Corya, S.A., Andersen, S.W. et al. Olanzapine/fluoxetine combination use in rapid-cycling bipolar depression. NR476. 156th Annual Meeting of the American Psychiatric Association, San Francisco, May 17-21, 2003.
15. Sachs, G.S., Grossman, F., Ghaemi, S.N. et al. Combination of a mood stabilizer with risperidone or haloperidol for treatment of acute mania: A double-blind, placebo-controlled comparison of efficacy and safety. Am J Psychiatry 2002, 159: 1146-54.
16. Yatham, L.N., Grossman, F., Augustyns, L. et al. Mood stabilizers plus risperidone or placebo in the treatment of acute mania. International, double-blind, randomized controlled trial. Br J Psychiatry 2003, 182: 141-7.
17. Muller-Siecheneder, F., Muller, J., Hillert, A. et al. Risperidone versus haloperidol and amitriptyline in the treatment of patients with a combined psychotic and depressive syndrome. J Clin Psychopharmacol 1998, 18: 111-20.
18. Sajatovic, M., Brescan, D.W., Perez, D.E. et al. Quetiapine alone and added to a mood stabilizer for serious mood disorders. J Clin Psychiatry 2001, 62: 728-32.
19. Mullen, J., Jibson, M.D., Sweitzer, D. A comparison of the relative safety, efficacy, and tolerability of quetiapine and risperidone in outpatients with schizophrenia - the QUEST study. Clin Therapeutics 2001, 23: 1839-54.
20. Zarate, C.A. Jr., Rothschild, A., Fletcher, K.E., Madrid, A., Zapatel, J. Clinical predictors of acute response with quetiapine in psychotic mood disorders. J Clin Psychiatry 2000, 61: 185-189.
21. DelBello, M.P., Schwiers, M.L., Rosenburg, H.L., Strakowski, S.M. A double-blind, randomized, placebo-controlled study of quetiapine as adjunctive treatment for adolescent mania. J Am Acad Child Adolesc Psychiatry 2002, 41: 1216-23.
22. Mullen, J., Devine, N., Sweitzer, D. Quetiapine adjunctive therapy for acute mania associated with bipolar disorder. 156th meeting of the American Psychiatric Association, San Francisco, May 17-21, 2003.
23. Jones, M.W., Huizar, K. Quetiapine monotherapy for acute mania associated with bipolar disorder. NR432. 156th Annual Meeting of the American Psychiatric Association, San Francisco, May 17-21, 2003.
24. Keck, P.E. Jr., Versiani, M., Potkin, S. et al. Ziprasidone in the treatment of acute bipolar mania: A three-week, placebo-controlled, double-blind, randomized trial. Am J Psychiatry 2003, 160: 741-8.
25. Suppes, T., Webb, A., Paul, B. et al. Clinical outcome in a randomized 1-year trial of clozapine versus treatment as usual for patients with treatment-resistant illness and a history of mania. Am J Psychiatry 1999, 156: 1164-9.
26. Meltzer, H.Y., Alphs, L., Green, A.I. et al. Clozapine treatment for suicidality in schizophrenia: International Suicide Prevention Trial (Intersept). Arch Gen Psychiatry 2003, 60: 82-91.
27. Stahl, S.M. Dopamine system stabilizers, aripiprazole, and the next generation of antipsychotics, part 1: "Goldilocks" action at dopamine receptor. J Clin Psychiatry 2001, 62: 841-2.
28. Stahl, S.M. Dopamine system stabilizers, aripiprazole, and the next generation of antipsychotics, part 2: Illustrating their mechanism of action. J Clin Psychiatry 2001, 62: 923-4.
29. Jordan, S., Koprivica, V., Chen, R. et al. The antipsychotic aripiprazole is a potent, partial agonist at the human 5HT(1A) receptor. Eur J Pharmacol 2002, 441: 137-40.
30. Grunder, G., Carlsson, A., Wong, D.F. Mechanism of new antipsychotic medications. Arch Gen Psychiatry 2003, 60: 974-7.
31. Citrome, L.L., Josiassen, R., Bark, N.M. et al. Pharmacokinetics and safety of aripirazole and concomitant mood stabilizers. NR317. 55th Annual Meeting of the American Psychiatric Association, Philadelphia, May 18-23, 2002.
32. Kane, J.M., Carson, W.H., Saha, A.R. et al. Efficacy and safety of aripiprazole and haloperidol versus placebo in patients with schizophrenia and schizoaffective disorder. J Clin Psychiatry 2002, 63: 763-71.
33. Potkin, S.G., Saha, A.R., Kujawa, M.J. et al. Aripiprazole, an antipsychotic with a novel mechanism of action, and risperidone vs. placebo in patients with schizophrenia and schizoaffective disorder. Arch Gen Psychiatry 2003, 60: 681-90.
34. Carson, W.H., Saha, A.R., McQuade, R.D. et al. A open labeled extension study of aripiprazole. Presentation at the Annual Meeting of the American Psychiatric Association, Philadelphia, May 18-23, 2002.
35. Carson, W.H., Saha, A.R., McQuade, R.D. et al. A maintenance study of aripiprazole. Presentation at the American College of Neuropsychopharmacology, Puerto Rico, December 2002.
36. Cornblatt, B., Green, M.F., Carson, W. et al. A comparison of cognitive performance on aripiprazole versus olanzapine. Int J Neuropsychopharmacol 2002, 5 (Suppl. 1): S185.
37. Kane, J., Carson, W.H., Kujawam, M. et al. Aripiprazole in treatment-resistant schizophrenia: A 6 week double blind comparison study versus perphenazine. Schizophr Res 2004, 67: 155.
38. Saha, A.R., Brown, D., McEvoy, J. et al. Tolerability and efficacy of aripiprazole in patients with first episode schizophrenia: An open-labelled pilot study. Schizophr Res 2004, 67: 158.
39. Carson, W.H., Stock, E., Saha, A.R. et al. Meta-analysis of the safety and tolerability of aripiprazole. Schizophr Res 2002, 53: 186-7.
40. Casey, D.E., Daniel, D.G., Wassef, A.A. et al. Effect of Divalproex combined with olanzapine or risperidone in patients with an acute exacerbation of schizophrenia. Neuropsychopharmacology 2003, 28: 182-92.
41. Wirshing, D.A., Pierre, J.M., Erhart, S.M. Understanding the new and evolving profile of adverse drug effects in schizophrenia. Psychiatr Clin N Am 2003, 26: 16-190.
42. Dickson, R., Glazer, W. Neuroleptic-induced hyperprolactinemia. Schizophr Res 1999, 25: 575-86.
43. Welch, R., Chue, P. Antipsychotic agents and QT changes. J Psychiatry Neurosci 2000, 25: 154-60.
44. Keck, P.E. Jr., Marcus, R., Tourkodimitris, S. et al. A placebo-controlled, double-blind study of the efficacy and safety of aripiprazole in patients with acute bipolar mania. Am J Psychiatry 2003, 160: 1651-8.
45. Ketter, T.A. Evolving role of novel antipsychotics for the management of acute mania. 156th Annual Meeting of the American Psychiatric Association, San Francisco, May 17-21, 2003.
46. Bourin, M., Auby, P., Marcus, R.N. et al. Aripiprazole versus haloperidol for maintained treatment effect in acute mania. 156th Annual Meeting of the American Psychiatric Association, San Francisco, May 17-21, 2003.
47. Sachs, G., Sanchez, R., Marcus, R. et al. Aripiprazole vs. placebo in acute mania: Results from a second study. 55th Institute on Psychiatric Services, Boston, Oct 29-Nov 2, 2003.
48. Kujawa, M., Stringfellow, J., Hardy, S. et al. Efficacy, safety, and tolerability of aripiprazole in patients with schizoaffective disorder. Schizophr Res 2004, 67: 156.
49. American Diabetes Association (ADA). Consensus development conference on antipsychotic drugs and obesity and diabetes. Diabetes Care 2004, 27: 596-601.
50. Cassidy, F., Ahearn, E., Carroll, B.J. Elevated frequency of diabetes mellitus in hospitalized manic-depressive patients. Am J Psychiatry 1999, 156: 1417-20.